Premature atherosclerotic coronary heart disease driven by multiple risk factors is a major cause of morbidity and mortality among the 6 million patients in the United States with chronic renal failure. Consensus is that kidney failure and renal transplantation patients should be treated aggressively for dyslipidemia. Major medical literature databases were searched for published information about fluvastatin, a HMG-CoA reductase inhibitor, used in patients with impaired renal function. This article characterizes the dyslipidemia observed in these clinical settings and reviews the clinical experience with fluvastatin. Copyright (copyright) 2005 Taylor & Francis Inc.
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation / H. Holdaas, A. Corsini. - In: RENAL FAILURE. - ISSN 0886-022X. - 27:3(2005), pp. 259-273.
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
A. CorsiniUltimo
2005
Abstract
Premature atherosclerotic coronary heart disease driven by multiple risk factors is a major cause of morbidity and mortality among the 6 million patients in the United States with chronic renal failure. Consensus is that kidney failure and renal transplantation patients should be treated aggressively for dyslipidemia. Major medical literature databases were searched for published information about fluvastatin, a HMG-CoA reductase inhibitor, used in patients with impaired renal function. This article characterizes the dyslipidemia observed in these clinical settings and reviews the clinical experience with fluvastatin. Copyright (copyright) 2005 Taylor & Francis Inc.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.